该词条未找到_海词词典

您要查找的是不是：

KDR tyrosine kinase KDR酪氨酸激酶
The name is soluble f-m-s-like tyrosine kinase one? 这种蛋白质叫做可溶解fms样酪氨酸激酶一，
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用?
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail. 详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
The ABL gene encodes a tyrosine kinase whose activity is tightly regulated. ABL基因编码一种活性受到严格调控的酪氨酸激酶。
FGFR3, a member of polypeptide growth factor family, is a tyrosine kinase receptor. FGFR3是这一多肽类生长因子的家族成员之一，它是一种酪氨酸激酶受体。
The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文综述了近年来酪氨酸激酶抑制剂的研究进展，包括抑制剂的结构和与激酶作用的药效团模型。
Isoflavone. Inhibitor of EGFR tyrosine kinase, blocking phosphatidylinositol turnover. 异黄酮类。抑制EGFR酪氨酸激酶。阻断磷脂酰肌糖的翻转。
STI571 could induce leukemia cells of ANLL into terminal differentiation by inhibiting c-kit tyrosine kinase. STI571对急性非淋巴细胞白血病原代细胞有诱导向同系终末分化的作用,对c-kit酪氨酸激酶有明显的抑制作用,且与药物浓度相关。
Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma. 目的:研究散发型甲状腺髓样癌酪氨酸激酶受体基因(RET)的突变情况。
OBJECTIVE:To discuss the progress and the clinical application evaluation of protein tyrosine kinase(PTK) inhibitors. 目的:探讨酪氨酸激酶抑制剂的进展与临床应用评价。
The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors are reviewed. 综述了EGFR的结构和作用以及近年来EGFR酪氨酸激酶抑制剂的研究进展。
Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor. 曲妥单抗是一种直接针对HER2酪氨酸激酶受体的单抗。
We got 10 phage clones which could bind with wild-type and mutant Bcr/Abl tyrosine kinase domain. （2）用菌体呈现随机7肽库对构建表达的激酶域蛋白进行了生物淘筛，得到了10个与两种类型激酶域均能结合的共用型噬菌体克隆。
Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002. 吉非替尼是EGFR酪氨酸激酶抑制剂中最早进入临床试验的口服药物，2002年首次于日本上市。
EGFR tyrosine kinase inhibitor is an investigative hot spot in targeted therapy of non-small cell lung cancer (NSCLC). 摘要EGFR靶向抑制剂，是目前NSCLC靶向治疗的研究热点之一。
Angiopoietin acts on Tie-2,which is a receptor tyrosine kinase specifically expressed on endothelial cells. 作用于内皮特异受体酪氨酸激酶酪氨酸激酶受体2。
Recently, novel antineoplastics were developed by preferentially targeting inhibition of such EGFR tyrosine kinase. 近年来,许多以此为靶点的新抗肿瘤药物陆续被开发,在多种肿瘤治疗中取得了令人鼓舞的疗效。